2019 (v1)
Publication
No description
Uploaded on: February 14, 2024
-
-
2021 (v1)Publication
Background: In young women, combined hormonal contraceptives can ameliorate menstrual pain and reduce menstrual loss, but their efficacy in adenomyosis has not been proven. The aim of this study was to investigate whether ultrasound features of adenomyosis are modified by a combined hormonal contraceptive containing dienogest. Methods:...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2019 (v1)Publication
No description
Uploaded on: May 12, 2023 -
2020 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2019 (v1)Publication
Introduction: Endometriosis is a chronic benign estrogen-dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity. Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating...
Uploaded on: May 12, 2023 -
2016 (v1)Publication
Study question: What are the effects of dienogest (DNG) on midkine (MK) production in women with endometriosis? summary answer: DNG-mediated down-regulation of MK in vivo and in vitro. what is known already: DNG is an oral progestin that alleviates painful symptoms of women with endometriosis with a favourable tolerability and safety profile....
Uploaded on: April 14, 2023 -
2020 (v1)Publication
BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndromes are among the best-known and most extensively studied hereditary cancer syndromes. Nevertheless, many patients who proved negative at BRCA genetic testing bring pathogenic mutations in other suppressor genes and oncogenes associated with hereditary breast and/or ovarian...
Uploaded on: April 14, 2023